×
Abstract P1-10-12: Differential benefit of intra-operative administration of ketorolac on breast cancer disease recurrence according to baseline body mass index
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-12

Nov 6th, 2018 - Background: According to the last estimates, 63% of the women in the US are either overweight or obese. Increased body mass index (BMI) has been recognized as a risk factor for developing breast cancer (BC) and associated with adverse survival. So far, few treatment modalities focusing on the biological features of BC patients with increased adiposity have been evaluated. In cancer patients, el...

Abstract P4-03-01: Causes of endocrine therapy resistance: An in-depth genomic analysis of resistant multidrug ER+ breast cancers
http://cancerres.aacrjournals.org/content/78/4_Supplement/P4-03-01

Feb 4th, 2019 - Background: 70% of all breast cancers (BCs) are ER+. Not all ER+ cancers respond to endocrine therapy (ET) and many eventually develop resistance. The aim was to perform in-depth genomic analysis of both primary resistant BCs, that do not respond to ET, and cancers which progress (>40% increase in size) after an initial response as they acquire resistance (AQR) to ET. Methods: A unique series o...

Abstract P1-10-08: Development of a first-in-class oral selective ERα covalent antagonist (SERCA) for the treatment of ERαWT and ERαMUT breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-08

Nov 7th, 2018 - Mutations in estrogen receptor alpha (ERα) are detected in up to 30% of breast cancer patients who have relapsed during endocrine therapy. ERα mutations functionally confer resistance to existing classes of endocrine therapies, likely through gaining constitutive activity. The fact that current ER-directed therapies are only partially effective in the ERα mutant setting, and that a significant ...

Abstract P1-10-05: ICEC0942, a new oral selective inhibitor of the cell cycle and transcriptional regulator CDK7 for the treatment of estrogen receptor positive and negative breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-05

Nov 8th, 2018 - CDK7 is remarkable as a key regulator of both cell cycle progression and gene expression. CDK7 promotes cell cycle progression by phosphorylating cell cycle CDKs in the T-loop, thus stimulating their activities. Additionally, phosphorylation of RNA polymerase II (PolII) by CDK7 is required for transcription initiation. Deregulation of cell cycle and transcription processes is common to most can...

Abstract P6-11-19: Efficacy and patient acceptability of the DigniCaP ScalpCooler to prevent hair loss in breast cancer patients receiving adjuvant chemotherapy
http://cancerres.aacrjournals.org/content/78/4_Supplement/P6-11-19

Aug 27th, 2018 - Background: Alopecia is a common and distressing adverse effect in breast cancer (BC) patients (pts) receiving adjuvant chemotherapy. The aim of the study was to assess the effectiveness and safety of this device to prevent chemotherapy-induced alopecia in early breast cancer patients (EBCP) receiving adjuvant treatment. The quality of life of pts was also evaluated. Patients and methods: From ...

Abstract P1-10-07: Efficacy and safety results from a randomized, phase II study of CC-486 in combination with fulvestrant in postmenopausal women with estrogen receptor–positive (ER+), human epide...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-07

Nov 10th, 2018 - Background: Most patients diagnosed with breast cancer have ER+ tumors. Treatment of ER+ MBC typically involves endocrine therapy, including aromatase inhibitors and selective ER modulators such as tamoxifen; however, many patients develop resistance. Fulvestrant, an ER antagonist, is a commonly prescribed second- or third-line therapy for postmenopausal patients who have progressed on endocrin...

Abstract P2-04-04: Developing targeted therapeutic microbubbles for enhanced epigenetic drug delivery for breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-04-04

Feb 9th, 2019 - Background: In recent years, there has been great interest in developing drugs that modify epigenetic changes as new therapies for breast cancer (BC). There is evidence that aberrant epigenetic inactivation of genes, essential for normal cell growth, is involved in cancer. These modifications are potentially reversible therefore re-activation of genes in response to epigenetic drugs can result ...

Abstract P1-10-10: Tumor infiltrating lymphocytes (TILS) among high risk for recurrence breast cancer patients treated with tetrathimolybdate (TM)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-10

Nov 12th, 2018 - Background: Tumor infiltrating lymphocytes (TILs) evaluated in the primary tumor biopsy or surgical resection have been well established as having prognostic significance in patients with triple negative breast cancer (TNBC) and HER2+ breast cancer treated with adjuvant chemotherapy (Savas et. al, Nat Rev Clin Oncol 2016). In TNBC, stromal TILs behave as a continuous variable with every 10% inc...

Abstract P2-06-03: Clinicopathologic characteristics and genomic essence analyses revealed estrogen receptor positive, progesterone receptor negative and human epidermal growth factor receptor 2 ne...
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-06-03

Mar 19th, 2019 - Background: Estrogen receptor positive/ progesterone receptor negative/ human epidermal growth factor receptor 2 negative (ER+/PR-/HER2-) tumors define a distinct subtype of ER+ breast cancer, characterized by poor response to endocrine therapy and poor prognosis. The genomic landscape of ER+/PR-/HER2- tumor has yet to be systematically studied,and driver events for tumor progression and endocr...

Abstract P5-04-03: Aggressiveness of epithelial cancers is independent of epithelial-to-mesenchymal transition
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-04-03

Feb 11th, 2019 - Background: Epithelial-to-Mesenchymal Transition (EMT)is postulated to be an important step in cancer progression and controlled by multiple mechanisms including EMT transcription factors (EMT-TFs) and splicing factors such as Epithelial Splicing Regulatory Proteins (ESRP1 and ESRP2). We previously have shown that the expression of ESRP1 and ESRP2 have significantly elevated in cases with high ...

Abstract P1-10-02: A phase II study of copper-depletion using tetrathiomolybdate in patients with breast cancer at high risk for recurrence: Updated results
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-02

Nov 14th, 2018 - Background: Metals have emerged as a viable therapeutic target for a new generation of anti-cancer and anti-metastatic agents. Copper, an essential trace element, serves as an important catalytic cofactor in several biological functions and has emerged as an essential factor in carcinogenesis. Among other elements, bone marrow derived VEGFR2+ endothelial progenitor cells (EPCs) and copper-depen...

Abstract P1-10-03: Precision therapeutic combinations are synergistic against triple negative breast cancer using compensatory pathways
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-03

Nov 15th, 2018 - Introduction: Triple negative breast cancer (TNBC) accounts for 15% of all breast cancer cases in the United States, and despite its lower incidence, contributes to a disproportionately higher rate of morbidity and mortality compared to other breast cancer subtypes. In an effort to treat TNBC, a cancer that has no targeted therapies, many have chosen to experiment with combinations of drugs tha...

Abstract P1-10-11: Multivalent exposure of trastuzumab on iron oxide nanoparticles enhances antitumor activity and weakens drug resistance in HER2+ breast cancer cells
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-10-11

Nov 16th, 2018 - Background: The identification of new strategies aimed to optimize the treatment of breast cancer and its metastases represents a great technical and medical challenge. Target-specific therapies, such as Trastuzumab (TZ), have revolutionized the clinical scenario in certain subsets of cancer. However, the huge variability in response to therapy and the frequent onset of drug resistance in patie...

Abstract P1-01-15: Investigation of phosphoserine aminotransferase 1 and its role in breast cancer progression
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-01-15

Mar 23rd, 2019 - Metastasis and endocrine resistance are two factors that complicate therapeutic intervention in breast cancer patients and lead to poorer overall survival. Metastasis is known to be responsible for 90% of cancer related deaths, and is especially prevalent in triple negative breast cancer (TNBC); while endocrine resistance can affect up to 50% of patients diagnosed with estrogen receptor positiv...

Abstract P1-01-23: Hypoxia induced centrosome amplification via HIF-1α/Plk4 signaling axis associates with poorer overall survival in TNBC
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-01-23

Mar 24th, 2019 - Background: Centrosome amplification (CA) which refers to presence of supernumerary or abnormally large centrosomes drives tumor progression by promoting chromosomal instability and the generation of aggressive tumor clones. Although the role of CA in cancer progression is well-defined, no studies have yet discussed how CA is induced in tumor cells. We report here that intra-tumoral hypoxia, wh...

Abstract P1-01-14: The hemidesmosome protein collagen 17A1 is required for collective invasion and growth of mammary tumor organoids
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-01-14

Mar 25th, 2019 - Background: Invasion is a fundamental step in metastasis, the leading cause of breast cancer-related death. We have shown previously that primary breast tumors invade collectively as clusters of cancer cells (Cheung et al. Cell 2013). These clusters are led by a small subpopulation of cancer cells that highly express the basal epithelial protein cytokeratin 14 (K14) and other stem cell genes (C...

Abstract P2-11-06: Analysis of cardiac events among node positive breast cancer (NPBC) patients treated with three-dimensional conformal radiation therapy (3D-CRT)
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-11-06

Nov 19th, 2018 - Background: Regional nodal irradiation (RNI) in addition to the chest wall and/or breast can maximize local regional control and improve overall survival, but has been associated with late cardiac morbidity. We examined NPBC patients treated with RNI using 3D-CT based radiation therapy (RT) to evaluate incidence and type of cardiac events. Methods: Between 2000 and 2007, 156 NPBC patients were ...

Abstract P2-05-02: Functional genomic screening identifies ubiquitin-specific protease 11 (USP11) as a novel regulator of ER-alpha transcription in breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-05-02

Feb 17th, 2019 - Approximately 70% of breast cancers overexpress the estrogen receptor α (ERα) and depend on this key transcriptional regulator for growth and differentiation. The discovery of novel mechanisms controlling ERα function represent major advances in our understanding of breast cancer progression and potentially offer attractive new therapeutic opportunities. Here, we investigated the role of deubiq...

Abstract P2-11-16: The safety and pathological impact of neoadjuvant radiotherapy for local advanced breast cancer undergoing mastectomy and autologous reconstruction
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-11-16

Nov 20th, 2018 - Introduction Delayed breast reconstructions are preferred if post mastectomy radiotherapy is indicated due to lower complication rates compared to immediate permanent implant or autologous reconstructions (AR) but cosmetic outcomes are inferior. Radiotherapy has a deleterious effect on implants and autologous tissue and often an interim tissue expander is place which has inherent pain and compl...

Abstract P2-05-04: Deregulation of A-to-I RNA editing is associated with poor prognosis in HER2+ breast cancers in the neoALTTO trial
http://cancerres.aacrjournals.org/content/78/4_Supplement/P2-05-04

Feb 18th, 2019 - Background A-to-I RNA editing, a post-transcriptional modification of the RNA catalyzed by the ADAR family of enzymes, is emerging as a widespread phenomenon in breast cancer (BC). A-to-I RNA editing is more frequent in the highly repetitive Alu regions but can affect both coding and non-coding regions. It has been shown to greatly impact cell functionality. In a recent report, we have shown th...